May 29th 2023
Data supports ANX007 as the first complement therapy to preserve visual acuity, achieving statistically significant protection, but reduction in rate of geographic atrophy lesion growth did not reach statistical significance.
Iveric Bio announces vision loss reduction data in geographic atrophy from avacincaptad pegol GATHER TrialsMarch 3rd 2023
According to the company, post-hoc time-to-event analysis signals up to 59% risk reduction in rate of vision loss compared to sham treatment at 12 months. The analysis will be presented at the ARVO Annual Meeting from April 23-27 in New Orleans.
Pegcetacoplan approved by FDA for geographic atrophy secondary to AMDFebruary 17th 2023
Apellis received FDA approval for intravitreal pegcetacoplan (SYFOVRE) to treat geographic atrophy secondary to AMD. This news follows the submission of the 24-month phase 3 data in November 2022.
Angiogenesis 2023: Visual functional loss in geographic atrophyFebruary 10th 2023
In a presentation at the 2023 Angiogenesis, Exudation, and Degeneration program, Usha Chakravarthy, PhD, FRCOphth, CBE, presented data from the trial of lampalizumab, which is peeling back some of the mystery shrouding geographic atrophy.